These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 8458488)

  • 1. Long-term naltrexone treatment normalizes the pituitary response to gonadotropin-releasing hormone in polycystic ovarian syndrome.
    Lanzone A; Apa R; Fulghesu AM; Cutillo G; Caruso A; Mancuso S
    Fertil Steril; 1993 Apr; 59(4):734-7. PubMed ID: 8458488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pituitary function is altered during the same cycle in women with polycystic ovary syndrome treated with continuous or cyclic oral contraceptives or a gonadotropin-releasing hormone agonist.
    Ruchhoft EA; Elkind-Hirsch KE; Malinak R
    Fertil Steril; 1996 Jul; 66(1):54-60. PubMed ID: 8752611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dynamics of plasma gonadotropin and sex steroid release in polycystic ovarian disease after pituitary-ovarian inhibition with an analog of gonadotropin-releasing hormone.
    Calogero AE; Macchi M; Montanini V; Mongioi A; Maugeri G; Vicari E; Coniglione F; Sipione C; D'Agata R
    J Clin Endocrinol Metab; 1987 May; 64(5):980-5. PubMed ID: 3104389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inverse relationship between luteinizing hormone and body mass index in polycystic ovarian syndrome: investigation of hypothalamic and pituitary contributions.
    Pagán YL; Srouji SS; Jimenez Y; Emerson A; Gill S; Hall JE
    J Clin Endocrinol Metab; 2006 Apr; 91(4):1309-16. PubMed ID: 16434454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pituitary responsiveness to gonadotrophin-releasing hormone agonist stimulation: a dose-response comparison of luteinizing hormone/follicle-stimulating hormone secretion in women with polycystic ovary syndrome and normal women.
    Cheung AP; Chang RJ
    Hum Reprod; 1995 May; 10(5):1054-9. PubMed ID: 7657740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changing pituitary reactivity to follicle-stimulating hormone and luteinizing hormone-releasing hormone after induced ovulatory cycles and after anovulation in patients with polycystic ovarian disease.
    Blankstein J; Rabinovici J; Goldenberg M; Shaley J; Mehta A; Serr DM; Mashiach S
    J Clin Endocrinol Metab; 1987 Dec; 65(6):1164-7. PubMed ID: 3119650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of dexamethasone and dexamethasone plus naltrexone on pituitary response to GnRH and TRH in normal women.
    la Marca A; Torricelli M; Morgante G; Lanzetta D; De Leo V
    Horm Res; 1999; 51(2):85-90. PubMed ID: 10352398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ovarian control of pituitary sensitivity of luteinizing hormone secretion to gonadotropin-releasing hormone in women with the polycystic ovary syndrome.
    Dafopoulos K; Venetis C; Pournaras S; Kallitsaris A; Messinis IE
    Fertil Steril; 2009 Oct; 92(4):1378-1380. PubMed ID: 19467538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of mifepristone (RU486) on the pituitary response to gonadotrophin releasing hormone in women.
    Kazem R; Messinis LE; Fowler P; Groome NP; Knight PG; Templeton AA
    Hum Reprod; 1996 Dec; 11(12):2585-90. PubMed ID: 9021355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prolonged opioid blockade with naltrexone and luteinizing hormone modifications in women with polycystic ovarian syndrome.
    Cagnacci A; Soldani R; Paoletti AM; Falqui A; Melis GB
    Fertil Steril; 1994 Aug; 62(2):269-72. PubMed ID: 8034071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation between integrated LH and FSH levels and the response to luteinizing hormone relasing factor (LRF).
    Mortimer RH; Fleischer N; Lev-Gur M; Freeman RG
    J Clin Endocrinol Metab; 1976 Dec; 43(6):1240-9. PubMed ID: 794076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pituitary response to bolus and continuous intravenous infusion of luteinizing hormone-releasing factor in normal women and women with polycystic ovarian syndrome.
    Mortimer RH; Lev-Gur M; Freeman R; Fleischer N
    Am J Obstet Gynecol; 1978 Mar; 130(6):630-4. PubMed ID: 345810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response of gonadotropins to pituitary stimulation with luteinizing hormone releasing hormone is a more specific than sensitive parameter for the polycystic ovary syndrome.
    Steck T; Wernze H; Albert PJ
    Gynecol Endocrinol; 1991 Dec; 5(4):235-47. PubMed ID: 1796746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alterations in gonadotropin-releasing hormone-dependent gonadotropin secretion in rats with polycystic ovaries.
    Carrière PD; Brawer JR; Farookhi R
    Biol Reprod; 1991 Nov; 45(5):685-90. PubMed ID: 1661616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Naltrexone effect on pulsatile GnRH therapy for ovulation induction in polycystic ovary syndrome: a pilot prospective study.
    Fulghesu AM; Ciampelli M; Belosi C; Apa R; Guido M; Caruso A; Mancuso S; Lanzone A
    J Endocrinol Invest; 2001; 24(7):483-90. PubMed ID: 11508781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pituitary-ovarian response to the gonadotrophin-releasing hormone-agonist test in anovulatory patients with polycystic ovary syndrome: predictive role of ovarian stroma.
    Fulghesu AM; Angioni S; Belosi C; Apa R; Selvaggi L; Ciampelli M; Iuculano A; Melis GB; Lanzone A
    Clin Endocrinol (Oxf); 2006 Sep; 65(3):396-401. PubMed ID: 16918963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence of a distinct derangement of opioid tone in hyperinsulinemic patients with polycystic ovarian syndrome: relationship with insulin and luteinizing hormone secretion.
    Lanzone A; Fulghesu AM; Cucinelli F; Ciampelli M; Caruso A; Mancuso S
    J Clin Endocrinol Metab; 1995 Dec; 80(12):3501-6. PubMed ID: 8530590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The utility of the gonadotrophin releasing hormone (GnRH) test in the diagnosis of polycystic ovary syndrome (PCOS).
    Lewandowski KC; Cajdler-Łuba A; Salata I; Bieńkiewicz M; Lewiński A
    Endokrynol Pol; 2011; 62(2):120-8. PubMed ID: 21528473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subcutaneous administration of pulsatile gonadotropin-releasing hormone decreases serum follicle-stimulating hormone and luteinizing hormone levels in women with polycystic ovary syndrome: a preliminary study.
    Graña-Barcia M; Liz-Lestón J; Lado-Abeal J
    Fertil Steril; 2005 May; 83(5):1466-72. PubMed ID: 15866586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ovarian 17-hydroxyprogesterone hyperresponsiveness to gonadotropin-releasing hormone (GnRH) agonist challenge in women with polycystic ovary syndrome is not mediated by luteinizing hormone hypersecretion: evidence from GnRH agonist and human chorionic gonadotropin stimulation testing.
    Ibañez L; Hall JE; Potau N; Carrascosa A; Prat N; Taylor AE
    J Clin Endocrinol Metab; 1996 Nov; 81(11):4103-7. PubMed ID: 8923867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.